A $108 Million Bet on Europe's Next-Gen Medical Breakthroughs

Jan de Vries · 2026-08-31

Let's talk about a major move in European health tech. Stockholm-based Elekta just secured a massive financial boost, and it's a clear signal about where innovation is headed. They've landed a loan of up to $108 million from the European Investment Bank (EIB). That's the EU's main financing arm, and this isn't just spare change. It's a strategic play. The funding comes from the EIB's TechEU program, which is all about doubling down on Europe's strengths in critical tech. Think of it as the EU putting its money where its mouth is on health research and staying competitive in advanced medicine. ### Why This Funding Matters Karl Nehammer, the EIB's Vice-President, put it perfectly. He said, "Europe has world-leading medical-technology companies and we need to make sure they can continue investing and innovating here. This financing will support the next generation of cancer and neurological treatments." That's the core of it. This loan isn't just for Elekta's balance sheet. It's designed to cover about half of a larger $216 million research program the company has planned between 2026 and 2029. Most of that groundbreaking work will happen right in Europe, split between Sweden and the Netherlands. It's part of a bigger picture. Just in 2025, the EIB Group signed over $108 billion in new financing across more than 870 projects. Their focus areas tell a story: climate action, digitalization, security, and yes, social infrastructure like healthcare. ### Who is Elekta, Anyway? If you're not in the MedTech world, you might not know them. But you should. Founded back in 1972 and listed on Nasdaq Stockholm, Elekta is a heavyweight in precision radiation medicine. They're fighting some of our toughest battles: - Brain tumours - Breast cancer - Kidney, lung, pancreatic, and prostate cancers - Certain neurological disorders Their approach is built on three pillars: adaptive radiotherapy, precision treatment delivery, and integrated clinical workflows. The scale is staggering. Their technology treats more than 2 million patients every single year. They've got a team of around 4,000 people spread across offices in more than 40 countries, reaching over 120 markets worldwide. ### The Real-World Impact So, what does this cash actually do? Klara Eiritz, Elekta's CFO, connects it directly to the challenges doctors face. "As demand for cancer care continues to grow, healthcare providers are looking for solutions that help them treat more patients while maintaining quality and precision," she explained. This financing gives them the flexibility to stick to their long-term strategy. It's about funding innovation that improves outcomes for patients, makes hospitals more efficient, and honestly, just makes the whole experience better for people going through a tough time. The money will fuel their work across several key areas: - Radiotherapy - Radiosurgery - Brachytherapy - The crucial software platforms that plan and deliver these complex therapies The goal is to improve treatments for a wider range of conditions, from tumours in the brain and body to essential tremor and specific forms of epilepsy. At its heart, Elekta wants to make treatments more accurate and efficient, helping healthcare systems keep up with a growing number of patients. This isn't a one-off deal for the EIB. It follows other recent health tech investments in Europe, like a $21.6 million venture debt agreement with Finnish digital pathology firm Aiforia back in July. It feels like a pattern, doesn't it? A concerted effort to build and back European champions in a field that touches all of our lives. When you step back, it's more than a loan. It's a vote of confidence in Europe's ability to solve some of humanity's most pressing health problems, right from its own backyard.